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diabetes is a condition, which, if tackled properly can be controlled, allowing the patient to have a relatively normal quality of life. However, if left unattended, 
complications can be life-threatening. 
According to the International 
Diabetes Foundation, in 2014 there 
were 35,200 cases of diabetes in Malta, 
this not including those with impaired 
glucose tolerance and impaired fasting 
glucose, which can both lead to diabetes. 
This leaves Malta with the second 
highest percentage of diabetes in the 
Mediterranean, surpassed only by Cyprus. 
Due to the increasing problem of 
diabetes incidence in the Maltese islands, 
we must try to educate the general public 
as early as possible about the benefits of 
a healthy lifestyle with an emphasis on 
preventive measures. 
Prevention of type 2 diabetes occurs 
mainly through lifestyle changes such 
as physical activity and healthy eating. Apart from the 
psychological benefits, physical activity aids in maintaining 
weight loss, reducing blood pressure and heart rate, and 
increasing insulin sensitivity. 
Risk factors to avoid include smoking, which 
increases abdominal fat accumulation and insulin 
resistance, and stress/depression which may be 
linked to both diabetes and cardiovascular disease. 
Sleep deprivation (< 6 hours) impairs the balance 
of hormones regulating food intake and energy 
balance, whilst sleeping too much (> 9 hours) may 
also be associated with a higher risk of diabetes.
As our contribution to this education, the 
Malta Pharmaceutical Students’ Association 
(MPSA) holds numerous health campaigns 
where free blood glucose testing, blood 
pressure and BMI screening are carried out. 
Furthermore, an annual diabetes campaign is held during 
World Diabetes Day. At these events, information material is 
given out in order to prompt the public’s interest for further 
reading on the disease and its prevention as well as instill 
healthy lifestyle changes 
full-tIme VacancIes
1. medical representative (ref: 011015)
2. medical sales promoter (ref: 021015) 
Further details may be found on thesynapse.net. 
Please send CV, quoting the relevant reference 
number, together with a covering letter by 30th 
November to Human Resources Manager, 
Cherubino Ltd, Delf Building, Sliema Road, 
Gzira, GZR 1637, Malta  
or via e-mail: recruitment@cherubino.com.mt
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clinic for rent adjacent to a busY pharmacY in QaWra. call 9988 4517 for further details.
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1000 mg/62,5 mg
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Mini Abridged Prescribing Information: Please refer to full Summary of Product Characteristics (SPC) 
before prescribing. TRADE NAME: Augmentin SR. ACTIVE INGREDIENTS: Amoxicillin (as trihydrate) 
and potassium clavulanate. PRESENTATION: 1000 mg/62.5 mg prolonged-release tablets. Supplied in 
28 tablet packs. INDICATION: Treatment of community acquired pneumonia in adults and adolescents 
aged at least 16 years, caused or thought likely to be caused by penicillin-resistant Streptococcus 
pneumoniae. POSOLOGY & ADMINISTRATION: Oral use. Recommended dose of two tablets twice daily 
for seven to ten days. To minimise potential gastrointestinal intolerance, administer at the start of a meal. 
CONTRAINDICATIONS: Hypersensitivity (and past history of) to the active substances, to any penicillins 
or to any of the excipients. SPECIAL WARNINGS & PRECAUTIONS: Before initiating therapy careful 
enquiry of previous hypersensitivity reactions to beta-lactams. Where an infection is proven to be due 
to an amoxicillin susceptible organism, a switch to an amoxicillin-only preparation should be considered. 
Convulsions may occur in patients receiving high doses or who have impaired renal function. Concomitant 
use of allopurinol increase likelihood of allergic skin reactions. Prolonged use may occasionally result in 
overgrowth of non-susceptible organisms. Contains 29.3 mg (1.3 mmol) of sodium per tablet. Refer to SPC’s 
for full list of precautions. INTERACTIONS: Penicillins may reduce the excretion of methotrexate causing 
a potential increase in toxicity. Concomitant use of probenecid is not recommended. If co-administration 
with oral anticoagulants is necessary, the prothrombin time or international normalised ratio should be 
carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the dose of 
oral anticoagulants may be necessary. Clinical monitoring should be performed during the combination 
with mycophenolate mofetil and shortly after antibiotic treatment. PREGNANCY & LACTATION: Use 
should be avoided unless considered essential by the physician. UNDESIRABLE EFFECTS: Very common 
(≥1/10): diarrhoea. Common (≥1/100, <1/10): mucocutaneous candidosis, nausea, abdominal pain. 
Refer to SPC’s for full list of undesirable effects. AUTHORISATION NUMBER: AA 1051/00102. MARKETING 
AUTHORISATION HOLDER: GlaxoSmithKline Bulgaria EOOD. LEGAL CATEGORY: POM. DATE OF 
PREPARATION: July 2014. In order to ensure that this product information reflects the most 
up-to-date clinical and post-marketing surveillance data, please always refer to the latest 
Summary of Product Characteristics (SPC) which is available from GlaxoSmithKline (Malta) Ltd 
(Tel: +356 21238131). REPORTING ADVERSE EVENTS (AEs): If you become aware of any AEs, 
medication errors and/or use during pregnancy in association with GSK products, please 
report the event promptly to: GSK (Malta) Limited, 1, De la Cruz Avenue, Qormi QRM 2458, Malta 
(Tel: +356 21238131). Alternatively, any suspected AEs and medication errors can also be 
reported via the national Adverse Drug Reactions (ADRs) reporting system: Report forms can 
be downloaded from www.medicinesauthority.gov.mt/adrportal and posted to the Malta Medicines 
Authority, Post-licensing Directorate, 203, Level 3, Rue D’Argens, Gżira GŻR 1368, MALTA, or sent by email 
to postlicensing.medicinesauthority@gov.mt. 
✓ Unique bilayer tablet with 
immediate and sustained 
release delivery of amoxicillin 
provides superior efficacy 
against resistant pathogens1,2
✓ Recommended by leading 
Guidelines in the treatment 
of Community Acquired 
Pneumonia3,4
✓ Most common adverse 
effects are diarrhoea, nausea, 
vomiting and mucocutaneous 
candidiasis5
✓ Indicated for use in adults & 
adolescents aged ≥16 years; 
2 tablets BD for 7-10 days5
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solIdarIty matters 
The Kamra tal-Ispiżjara ta’ Malta is making a call 
for solidarity for Kristen Zammit, a pharmacist who 
is currently having medical issues that have required 
repeated surgery in the UK. 
A Solidarity Fund Account with HSBC has been opened: 
Bank Account number - 009122706051 
and IBAN - MT27MMEB44093000000009122706051. 
Your contribution Would be GreatlY appreciated.
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